Mesalazine, also known as 5-aminosalicylic acid or 5-ASA, has been a cornerstone of inflammatory bowel disease management for decades. It is prescribed to both quell active flares of ulcerative colitis and Crohn’s disease and to keep those diseases in remission over the long term. Because it is generally well tolerated, patients often take it for years with little thought. Yet the new report underscores that even this familiar molecule can provoke serious lung injury. Drug-induced eosinophilic pneumonia occurs when an offending medication triggers an influx of eosinophils into the alveolar air spaces and the interstitial tissue of the lungs, impairing oxygen exchange and producing cough, breathlessness, and infiltrates visible on chest imaging. Diagnosis typically rests on a compatible drug history, elevated eosinophils in peripheral blood or bronchoalveolar lavage fluid, characteristic imaging, and exclusion of infection and other causes.

What makes this case exceptional is timing. In the vast majority of reported instances, mesalazine-related lung injury emerges two to six months after treatment begins, a lag that can easily lull clinicians into overlooking the drug as a culprit. The literature contains only a handful of cases in which symptoms appeared within ten days of the first dose, and the present patient, whose cough began on day seven, now ranks among the earliest ever recorded. By the time she was referred to hospital on day 39, chest radiography showed worsening consolidation in the right upper lung field along with a pleural effusion. Computed tomography demonstrated diffuse consolidation concentrated in the right upper lobe. Her vital signs remained stable, with an oxygen saturation of 96 percent on room air, but her white cell differential told a striking story: eosinophils made up 37.8 percent of a total count of 9,700 cells per microliter, and her C-reactive protein was mildly elevated at 2.67 mg/dL.

To pin down the diagnosis, clinicians turned to bronchoscopy. Bronchoalveolar lavage returned fluid with a total cell count of 5.88 × 10⁶ per milliliter, of which an extraordinary 78.6 percent were eosinophils, a signature finding in eosinophilic lung disease. Transbronchial biopsy and transbronchial lung cryobiopsy, a technique that freezes a larger sample of lung tissue for histological analysis, revealed dense eosinophilic infiltration in both the alveolar spaces and the interstitium. Bacterial and mycobacterial cultures and cytology were all negative, ruling out infection and malignancy. With the drug withdrawn, the clinical course became its own confirmation: chest radiography began improving just two days after mesalazine was stopped, the patient’s cough resolved within a month, and pulmonary infiltrates and peripheral eosinophilia had normalized six weeks later, all without corticosteroid therapy. She was subsequently transitioned to vedolizumab, a gut-selective biologic, for her ulcerative colitis, and the pneumonia did not recur.

Behind this single patient stands a much larger body of evidence assembled by the reporting team. Searching MEDLINE and screening references from prior reviews, the authors identified 57 additional cases of mesalazine-induced lung injury, bringing the total analyzed to 58. The demographic picture is instructive: patients ranged from 14 to 84 years of age, with a median of 35 and a peak in the third decade of life, and women outnumbered men 34 to 24. Ulcerative colitis accounted for 84 percent of underlying diagnoses, with Crohn’s disease making up most of the remainder. Eosinophilic pneumonia was the most common pattern of injury, representing 43 percent of cases, followed by interstitial pneumonia at 27 percent and organizing pneumonia at 10 percent. Most patients, 67 percent, showed bilateral infiltrates, though unilateral disease, as in this case, does occur and can mislead clinicians toward an infectious diagnosis.

The timing data from that literature review are perhaps the most clinically valuable takeaway. While lung injury typically develops two to six weeks after initiation, roughly 10 percent of cases occur within the first two weeks, and only two cases on record, including this one, manifested within ten days. In a focused analysis of 18 well-documented eosinophilic pneumonia cases, symptom onset ranged from seven days to fourteen months, with 70 percent occurring within two months. The median cumulative dose at onset was 81 grams of mesalazine; the present patient had consumed only about 14 grams when her symptoms began. That discrepancy carries real mechanistic weight, because a reaction that ignores both the duration of exposure and the total dose ingested is the hallmark of hypersensitivity rather than toxicity.

That mechanistic distinction matters for how clinicians think about drug safety. Drug-induced lung injury generally arises through two principal pathways: direct cytotoxic damage to alveolar epithelial or endothelial cells, which tends to be dose-related, and immune-mediated inflammation, which can erupt unpredictably at any exposure level. The evidence points firmly toward the immune pathway for mesalazine. Researchers propose that the drug may skew immune signaling toward a Th2-dominant response, in which cytokines such as interleukin-5 drive the production, recruitment, and activation of eosinophils, ultimately seeding them in lung tissue. Pharmacokinetic data reinforce the plausibility of a hypersensitivity mechanism: approximately 20 to 30 percent of orally administered mesalazine and about 10 percent of rectal formulations are absorbed systemically, and eosinophilic pneumonia has been reported even after rectal administration, indicating that small systemic exposures can suffice to ignite the reaction.

The case also settles a long-standing question about the older drug sulfasalazine, a prodrug that is metabolized in the gut into mesalazine and sulfapyridine. When eosinophilic pneumonia occurred in patients taking sulfasalazine, toxicity was often attributed to the sulfapyridine moiety. But the accumulating reports of identical lung injury with mesalazine alone suggest that the 5-aminosalicylic acid molecule itself is capable of triggering the immune response. For the millions of patients with inflammatory bowel disease who take 5-ASA compounds worldwide, this reframing means that no formulation of the drug class can be considered free of pulmonary hypersensitivity risk, however rare that risk may be in absolute terms.

One intriguing wrinkle in the present case is the patient’s respiratory history. She had suspected bronchial asthma and used inhaled corticosteroids as needed, and her fractional exhaled nitric oxide, a noninvasive marker of eosinophilic airway inflammation, was elevated at 51 parts per billion. The authors caution that this reading may have reflected pre-existing asthmatic airway inflammation rather than pneumonia alone, and they note that only one previously reported mesalazine lung-injury patient had a history of bronchial asthma. Whether underlying allergic airway disease can accelerate the onset of drug-induced eosinophilic pneumonia remains uncertain, but the possibility offers a concrete hypothesis for future research and a reason for heightened vigilance in asthmatic patients starting the drug.

The practical message for clinicians and patients alike is one of awareness rather than alarm. Corticosteroids, the usual mainstay of eosinophilic pneumonia treatment, are not always necessary; simple drug withdrawal can be sufficient when respiratory status is stable, as this case demonstrates. Yet some patients have received prednisolone out of concern that stopping mesalazine might precipitate a relapse of their inflammatory bowel disease, illustrating the delicate balancing act physicians face. The authors’ conclusion is straightforward: eosinophilic pneumonia can develop early in the treatment course, and drug-induced lung injury should be considered whenever respiratory symptoms or pulmonary infiltrates appear during mesalazine therapy. For a drug taken daily by so many, recognizing that the lungs can protest within a single week of the first tablet may make the difference between a swift, uncomplicated recovery and a prolonged diagnostic odyssey.

Subject of Research: Rapid-onset mesalazine-induced eosinophilic pneumonia occurring seven days after drug initiation

Article Title: Rapid Onset of Mesalazine‐Induced Eosinophilic Pneumonia Manifesting 7 Days After Initiation: A Case Report

Article References: Inazaki, T., Takeda, K., Iwasaki, M., Tajima, H., Shionoya, Y., Hirama, R., Sato, S., Naito, A., Kawasaki, T., Ikari, J., Kageyama, S., Ikeda, J.-I., & Suzuki, T. (2026). Rapid Onset of Mesalazine‐Induced Eosinophilic Pneumonia Manifesting 7 Days After Initiation: A Case Report. Respirology Case Reports, 14(9), Article e70758. https://doi.org/10.1002/rcr2.70758

Image Credits: AI Generated

DOI: 10.1002/rcr2.70758

Keywords: mesalazine, eosinophilic pneumonia, ulcerative colitis, drug-induced lung injury, inflammatory bowel disease, bronchoalveolar lavage, hypersensitivity pneumonitis, 5-aminosalicylic acid, adverse drug reaction, respirology, eosinophils, case report

The patient arrived at the hospital with a low-grade fever and a facial rash, one week after close contact with his daughter, who had been suffering from upper respiratory symptoms. Two years earlier he had been diagnosed with interstitial lung disease, suspected to be bird-related chronic hypersensitivity pneumonitis, a form of inflammatory lung injury driven by exposure to avian antigens such as those from feather duvets and down jackets. His condition had been managed with systemic corticosteroids, which had been carefully tapered and discontinued several months before admission, and he had been rigorously counseled to avoid avian exposures. A former smoker with a 38 pack-year history, he initially received oral levofloxacin from his local physician without improvement, prompting referral to the authors’ hospital.

On admission the clinical picture was deceptively subtle. He was alert, his temperature was 37.0 degrees Celsius, and his oxygen saturation sat at 90 percent on room air while fine crackles could be heard bilaterally and a mild facial rash was visible. Laboratory evaluation showed only mild inflammation, with a C-reactive protein level of 0.89 mg/dL, and importantly, serum KL-6 and surfactant protein D, biomarkers commonly used to track interstitial lung disease activity, remained unchanged from his baseline values. An extensive infectious workup was entirely negative, including serum beta-D-glucan, cytomegalovirus antigenemia, Aspergillus IgG and a multiplex polymerase chain reaction panel for common respiratory pathogens. Given the recent sick contact in the family and the facial rash, clinicians performed parvovirus B19 serology, which returned positive IgM and IgG antibodies, indicating a recent primary infection.

Imaging told a more alarming story. Chest radiography revealed decreased radiolucency in the bilateral middle and lower lung fields compared with films obtained only three months earlier, and high-resolution computed tomography demonstrated newly developed bilateral ground-glass opacities, a finding that in a patient with underlying fibrotic lung disease immediately raises concern for an acute exacerbation. Broad-spectrum antibiotics were started on the assumption of bacterial pneumonia, yet the opacities continued to progress, forcing the team to look deeper. Bronchoscopy was performed, and bronchoalveolar lavage fluid collected from the left B5 segment yielded a total cell count of 1.42 x 10^5 cells per milliliter with striking lymphocytic predominance of 63.5 percent, along with histiocytes at 33.8 percent, neutrophils at 1.0 percent and eosinophils at 1.7 percent.

The decisive result came from molecular testing of that lavage fluid: polymerase chain reaction was positive for parvovirus B19 DNA, directly demonstrating the virus within the lower respiratory tract during the acute phase of illness. Testing for Pneumocystis jirovecii was negative, no pathogenic organisms were isolated in culture, and cytology excluded malignancy. With a compatible exposure history, serologic confirmation of acute infection and viral DNA recovered from the lung itself, the clinicians concluded that the acute respiratory deterioration was associated with parvovirus B19, a diagnosis essentially never made in immunocompetent adults. During hospitalization the serum KL-6 and SP-D levels rose and the patient’s oxygen requirement climbed transiently to 3 liters per minute, reflecting genuine physiologic worsening rather than an incidental imaging finding.

Treatment took the form of high-dose pulsed corticosteroids, with methylprednisolone at 1000 mg per day, which produced rapid clinical and radiological improvement. The patient was transitioned to tapering oral prednisolone and discharged on Day 19 of his admission. At four-month follow-up he remained clinically stable, with sustained resolution of the opacities on serial chest radiographs. The favorable response is notable, though as the authors caution, it does not by itself settle the underlying mechanism, since the suspected bird-related hypersensitivity pneumonitis is generally considered more steroid-responsive than progressive fibrotic diseases such as idiopathic pulmonary fibrosis.

The diagnostic reasoning in this case illuminates a genuine clinical dilemma. Acute exacerbation of interstitial lung disease is defined by rapid respiratory deterioration within one month and the appearance of new bilateral ground-glass opacities on high-resolution computed tomography, criteria that this patient met. Yet distinguishing primary viral pneumonia from infection-triggered acute exacerbation remains notoriously difficult because the two entities overlap substantially in their clinical and radiological features. Previous prospective work cited by the authors detected respiratory viral infections in 19.2 percent of acute exacerbation cases, and such infections are associated with poor short-term outcomes. In this instance, common culprits such as influenza virus and the herpesviruses were excluded, and the absence of any alternative infectious agent or cardiac failure strengthened the case for parvovirus B19 as the causative trigger, although the authors acknowledge that unrecognized avian antigen exposure and progression of the underlying hypersensitivity pneumonitis could not be completely excluded, particularly given the lymphocytic, rather than neutrophilic, lavage profile.

The mechanistic plausibility of parvovirus B19 lung injury rests on well-characterized virology. The virus is a small, non-enveloped, single-stranded DNA virus that enters cells by binding the P antigen, a globoside receptor expressed not only on erythroid progenitors but also on pulmonary endothelial cells. Viral interaction with this receptor may cause endothelial injury, increased vascular permeability and diffuse alveolar damage, the histological substrate of acute lung injury. Experimental studies add a pro-fibrotic dimension: the viral non-structural protein NS1 has been shown to exacerbate fibrotic processes through activation of the TGF-beta/Smad signaling pathway, while the VP1-unique region of the capsid induces inflammatory cytokine release and disrupts epithelial barriers. In a lung already scarred by chronic interstitial disease, these processes could act as a ‘second hit’ that tips a compensated patient into acute exacerbation, providing a coherent biological explanation for what the radiographs and lavage findings captured.

The authors, Tomoki Kishaba and Satoshi Marumo of the Department of Respirology at Kitano Hospital, conclude that although the relative contributions of direct viral lung injury, infection-triggered exacerbation and progression of the underlying bird-related hypersensitivity pneumonitis could not be definitively disentangled, the case highlights the importance of considering parvovirus B19 as a potential contributor to acute respiratory deterioration, particularly in patients with underlying interstitial lung disease. For clinicians, the practical lessons are concrete: a facial rash or known ‘slapped cheek’ contact in an deteriorating ILD patient should prompt parvovirus B19 serology, and bronchoalveolar lavage with viral PCR can identify pathogens that routine respiratory panels miss, since parvovirus B19 does not appear on standard multiplex panels. For virologists and pulmonologists alike, the report underscores how much remains unknown about a virus that infects roughly half of humanity by adulthood, and the authors call for further studies to clarify the mechanisms underlying parvovirus B19-associated pulmonary involvement before such life-threatening presentations are encountered again.

Subject of Research: Acute respiratory deterioration associated with parvovirus B19 infection in a patient with interstitial lung disease.

Article Title: Acute Respiratory Deterioration Following Parvovirus B19 Infection in a Patient With Interstitial Lung Disease: A Case Report

Article References: Kishaba, T., Marumo, S., Nishida, Y., Nohara, E., Higashi, J., Aoki, S., Okura, C., Jinno, S., Tashima, N., Morimoto, C., Kitajima, T., & Inoue, D. (2026). Acute Respiratory Deterioration Following Parvovirus B19 Infection in a Patient With Interstitial Lung Disease: A Case Report. Respirology Case Reports, 14(9), Article e70751. https://doi.org/10.1002/rcr2.70751

Image Credits: AI Generated

DOI: 10.1002/rcr2.70751

Keywords: parvovirus B19, interstitial lung disease, acute exacerbation, hypersensitivity pneumonitis, viral pneumonia, bronchoalveolar lavage, ground-glass opacities, corticosteroids, respiratory infection, lung fibrosis, Acute, Respiratory